Safe, Inexpensive Indian Typhoid Vaccine Gets WHO Approval
A new and highly effective typhoid fever vaccine has been approved by the World Health Organization (WHO) for global use.
Bharat Biotech's Typhoid Conjugate Vaccine (TCV) against typhoid fever has received pre-qualification from the World Health Organisation (WHO), the vaccine manufacturer said on January 3.
International Health Metrics and Evaluation (IHME) estimates that in 2016, there were approximately 12 million cases of typhoid fever resulting in around 1,30,000 deaths.
The WHO pre-qualification enables the procurement and supplies of this life saving vaccine to UNICEF, the Pan-American Health Organization (PAHO) and GAVI (a vaccine alliance) supported countries.
The Hyderabad-based company claims that Typbar TCV is the world's first clinically proven TCV.
Typbar TCV has been evaluated in Human Challenge Studies at Oxford University and typhoid conjugate vaccines have been recommended by WHO's Strategic Advisory Group of Experts on Immunization (WHO-SAGE).
Typbar TCV is a result of dedicated product development at Bharat Biotech since 2001, where all aspects of the product profile were studied and evaluated in human clinical trials.
WHO-SAGE recommended the use of typhoid conjugate vaccines for use in infants between 6 and 23 months of age and catch up vaccinations for children between 2 and 15 years of age.
(Make sure you don't miss fresh news updates from us. Click here to stay updated)